IMVT · Immunovant
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Market Cap
6.873B
52 Wk Range
$21.86 - $45.42
Previous Close
$33.21
Open
$33.07
Volume
907,602
Day Range
$32.59 - $34.23
Enterprise Value
5.983B
Cash
722.3M
Avg Qtr Burn
-83.22M
Insider Ownership
55.90%
Institutional Own.
52.76%
Qtr Updated
Sep 30th 2026
